User: Guest  Login
Document type:
journal article 
Author(s):
Eckel, F; Schneider, G; Schmid, RM 
Title:
Pancreatic cancer: a review of recent advances. 
Abstract:
Pancreatic cancer is one of the most common causes of cancer-related death. Despite the advances of the molecular pathogenesis, pancreatic cancer remains a major unsolved health problem. Overall, the 5-year survival rate is< 5% and only approximately 20% of the 10% of patients with resectable disease survive 5 years. Recently, the European Study Group for Pancreatic Cancer 1 trial demonstrated substantially increased survival from adjuvant chemotherapy with 5-fluorouracil-folinic acid and preliminary data showed prolonged disease-free survival from adjuvant gemcitabine. Current palliative therapeutic approaches mostly focused on evaluating chemotherapy regimens in which gemcitabine is combined with a second cytotoxic agent. Recently, large randomised trials of combinations of gemcitabine with either capecitabine or with erlotinib demonstrated prolonged survival and 1-year survival rates of approximately 25%. The advance of molecular biology has led to the elucidation of molecular events that are important for pancreatic carcinogenesis and has provided a foundation for the development of novel chemotherapeutic and biological agents that appear to be promising and are likely to play a future role in the treatment of patients withadvanced pancreatic cancer. 
Journal title abbreviation:
Expert Opin Investig Drugs 
Year:
2006 
Journal volume:
15 
Journal issue:
11 
Pages contribution:
1395-410 
Language:
eng 
Print-ISSN:
1354-3784 
TUM Institution:
II. Medizinische Klinik und Poliklinik